Vivo Capital related stories
All articles and analysis
MacuLogix locks in $38.7 mln Series DPennsylvania-based MacuLogix, a medical device company in the optometry and ophthalmology industry, has secured $38.7 million in Series D round of financing. Vivo Capital led the round with participation from return backers Fisk Ventures, Roche Venture Fund, Berwind Private Equity and Life Sciences Greenhouse of Central Pennsylvania.
- Bolt Biotherapeutics pulls in $54 mln Series B
San Francisco Bay Area-based Bolt Biotherapeutics, a biotechnology company focused on the immune system, has secured $54 million in Series B financing. Pivotal bioVenture Partners led the round with participation from Nan Fung Life Sciences, Novo Holdings and Vivo Capital.
- Impel NeuroPharma scores $67.5 mln Series D
Seattle-based Impel NeuroPharma, a developer of therapies that treat central nervous system disorders with unmet medical needs, has raised $67.5 million in Series D financing. KKR and Norwest Venture Partners led the round with participation from return backers Vivo Capital, 5AM Ventures and venBio Partners.
- Vivo Capital raises $532 mln for fund
Vivo Capital, a healthcare investment firm, has closed its opportunity fund at $532 million. Vivo Opportunity Fund will focus on small to mid-cap public life sciences companies.
- Tot Biopharm attracts $102 mln Series B
Tot Biopharm, a Chinese maker of anti-tumor drugs, has raised $102 million in Series B funding. The investors included China Universal (Cayman) GP Limited, Center Laboratories Group, Vivo Capital, Chengwei Capital, Yuanta Financial Holdings Group and Cathay Capital.
- VC-backed Crinetics Pharmaceuticals debuts IPO
San Diego-based Crinetics Pharmaceuticals, a drug developer focused on rare endocrine diseases and endocrine-related tumors, has raised $102 million for its IPO after pricing its 6 million shares at $17 per share. The stock began trading July 18, 2018 on the NASDAQ under the ticker symbol "CRNX." J.P. Morgan Securities LLC, Leerink Partners LLC and Piper Jaffray & Co are the lead underwriters. Crinetics' pre-IPO backers include Versant Ventures, 5AM Ventures and Vivo Capital.
- VC-backed Tricida rolls out IPO
South San Francisco, California-based Tricida Inc, a developer of oral drug therapies that treat patients with chronic kidney disease, has raised about $222.3 million for its IPO after pricing its 11.7 million shares at $19 per share. The stock began trading June 28, 2018 on the NASDAQ under the ticker symbol "TCDA." Goldman Sachs, J.P. Morgan Securities LLC and Cowen and Company LLC are the lead underwriters. Tricida's pre-IPO backers include Wellington Management Company LLP, Venrock Healthcare Capital Partners, Cormorant Asset Management, OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital.
- Precision BioScience snags $110 mln Series B
Durham, North Carolina-based Precision BioScience, a genome editing system provider, has raised $110 million in Series B financing. ArrowMark Partners led the round with participation from other investors that included Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, Leerink Partners, venBio, F-Prime and Osage University Partners.